Optimizing Piperacillin Dosing in Pediatric Liver Transplant Recipients: A Case Series

Area of Science:

• Pharmacology
• Transplantation Medicine
• Pediatric Infectious Diseases

Background:

• Post-liver transplantation pathophysiological changes significantly alter antibiotic pharmacokinetics and pharmacodynamics.
• Piperacillin-tazobactam is a critical broad-spectrum antibiotic for pediatric liver transplant recipients.
• Limited pharmacokinetic data exists for piperacillin in this specific patient population.

Purpose of the Study:

• To characterize piperacillin pharmacokinetic parameters in pediatric liver transplant recipients.
• To assess target attainment of piperacillin therapy in this cohort.
• To provide dosing recommendations for optimizing piperacillin therapy.

Main Methods:

• A pharmacokinetic analysis was conducted on pediatric liver transplant recipients receiving piperacillin-tazobactam.
• Patients had preserved renal function and received a standardized dosing regimen.
• Bayesian pharmacokinetic modeling was used to estimate parameters and simulate target attainment against common pathogens.

Main Results:

• Eight pediatric liver transplant recipients were analyzed, with a median age of 8 months.
• The majority of patients (87.5%) exhibited piperacillin concentrations below the target (100% fT > MIC).
• Simulations indicated a need for adjusted dosing, including extended infusion times, for most patients to achieve therapeutic targets.

Conclusions:

• Piperacillin pharmacokinetics are highly unpredictable and variable in pediatric liver transplant recipients.
• Personalized antibiotic therapy is crucial for optimizing piperacillin efficacy in this vulnerable population.
• Further studies are warranted to refine dosing guidelines for piperacillin in pediatric liver transplant patients.